Literature DB >> 17621798

[Current therapeutic strategy for rheumatoid arthritis].

J Wollenhaupt1, R Alten, H Burkhardt, E Edelmann, E Gromnica-Ihle, A Krause, K Krüger, B Manger, H Lorenz, U Müller-Ladner, H Nüsslein, H G Pott, H Tony, M Schneider.   

Abstract

The success of the treatment of rheumatoid arthritis depends primarily on early diagnosis. In most cases, basic therapy begins with methotrexate. Depending on the stage and course of the disease (radiographically detected early erosion and/or progression), basic immunosuppressive therapy can be combined or supplemented with cytokine antagonists. Furthermore, for specific indications, several alternative active substances (DMARD monotherapies) are available. Today the goal of therapy is always remission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17621798

Source DB:  PubMed          Journal:  MMW Fortschr Med        ISSN: 1438-3276


  3 in total

1.  [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Authors:  K Krüger; J Wollenhaupt; K Albrecht; R Alten; M Backhaus; C Baerwald; W Bolten; J Braun; H Burkhardt; G Burmester; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; J Kuipers; A Krause; H-M Lorenz; B Manger; H Nüßlein; H-G Pott; A Rubbert-Roth; M Schneider; C Specker; H Schulze-Koops; H-P Tony; S Wassenberg; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

2.  [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Authors:  J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

3.  Regulation of type II collagen, matrix metalloproteinase-13 and cell proliferation by interleukin-1β is mediated by curcumin via inhibition of NF-κB signaling in rat chondrocytes.

Authors:  Jian Wang; Jie Ma; Jian-Hua Gu; Fu-Yong Wang; Xiu-Shuai Shang; Hai-Rong Tao; Xiang Wang
Journal:  Mol Med Rep       Date:  2017-06-14       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.